Expert Interview
A look at Dupixent's recent FDA approval for its new indication of EoE and the Phase 3 study(NCT03633617)
Ticker(s): REGNInstitution: University of Colorado Children's Hospital
- Part of a multidisciplinary program that is focused on eosinophilic GI disease (Gastrointestinal Eosinophilic Diseases Program) and sees over 300 patients per year with EoE.
- Prescribed or managed Dupixent in >10 patients with EoE and comorbid atopic conditions and familiar with the Phase 3 study(NCT03633617) of Dupilumab in Patients With Eosinophilic Esophagitis
- Clinical interests include esophageal diseases, Transnasal Endoscopy/ Esophagoscopy (TNE), Eosinophilic Esophagitis (EoE), eosinophilic gastritis, eosinophilic gastroenteritis, eosinophilic enteritis, eosinophilic colitis, general gastrointestinal diseases
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
